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Abstract: The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant 
mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos. 
SMRP, CA125, and CYFRA21-1 concentrations were determined in about 1,700 serum samples from 627 workers formerly exposed 
to asbestos. The impact of factors that could modify the concentrations of the tumor markers was examined with linear mixed models. 
SMRP values increased with age 1.02-fold (95% CI 1.01–1.03) and serum creatinine concentration 1.32-fold (95% CI 1.20–1.45). 
Levels differed by study centers and were higher after 40 years of asbestos exposure. CA125 levels increased with longer storage of the 
samples. CYFRA21-1 values correlated with age 1.02-fold (95% CI 1.01–1.02), serum creatinine 1.21-fold (95% CI 1.14–1.30) and 
varied by study centers due to differences in sample handling. Tumor marker concentrations are influenced by subject-related factors, 
sample handling, and storage. These factors need to be taken into account in screening routine.
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Introduction
Malignant  mesothelioma  (MM)  is  an  aggressive 
cancer  of  the  serous  membranes  highly  associated 
with asbestos exposure. The annual number of new 
MM cases in Western Europe is expected to rise, with 
a maximum in the next two decades. MM may account 
for as many as 250,000 deaths in the next 35 years.1 
Similar trends have been reported in many countries 
worldwide.2 The latency period of the tumor is up to 
40 years and symptoms occur in late stages of the 
disease. Up to date, MM is an incurable disease, but 
a combination of pemetrexed and cisplatin showed 
a  significantly  improved  response  rate  and  overall 
survival.3 An earlier diagnosis of tumors generally 
leads to more effective therapies and the same might 
be true for MM. Tumor markers may facilitate an early 
diagnosis of cancer. Measurement of tumor markers 
in blood is a feasible minimally invasive method and 
may be suitable for application in screening routine.4
A  promising  tumor  marker  for  MM  is  soluble 
mesothelin-related  peptides  (SMRP).5  SMRP  has 
increasingly been used as a marker for MM6 and has 
been found to be elevated in asbestos-exposed patients 
up to five years before onset of clinical symptoms, 
suggesting a potential role as a marker for the early 
diagnosis of MM.7 Additionally, SMRP may be help-
ful in diagnosis of lung cancer (LC).8 While a single 
tumor marker often lacks sufficient sensitivity and 
specificity,  combinations  of  markers  may  improve 
the diagnostic performance. CA125 and CYFRA21-1 
are additional candidates for a marker panel based on 
results in pleural effusions.9,10
To improve the use of tumor markers as screening 
tools for the early detection of cancer, their distribu-
tion in screening populations with regard to factors 
that might influence the marker levels has to be con-
sidered. Raised SMRP levels are observed in patients 
with renal failure and hypertension.5 CA125 values 
can increase in patients with cardiac dysfunction.11 
Tumor markers could also be influenced by age and 
gender, or factors like sample handling and storage 
conditions.12  Recently,  we  have  shown  that  SMRP 
exhibits  excellent  stability  regarding  frozen  stor-
age13 but for CA125 and CYFRA21-1 less details are 
known. To determine confounding factors with sig-
nificant influences on marker levels, tumor markers 
need to be analyzed in pre-clinical samples obtained 
prior to diagnosis.4 As asbestos is the main etiologic 
factor for MM, surveillance cohorts of asbestos work-
ers represent an appropriate study population for the 
evaluation of potential confounders.
The objective of this study was to analyze the dis-
tribution of serum SMRP, CA125, and CYFRA21-1 
in a cohort of workers formerly exposed to asbestos 
without MM or LC at the beginning of the surveil-
lance and to identify and evaluate potential factors 
with significant influence on tumor marker levels.
Material and Methods
study population
The study group of 627 German asbestos workers origi-
nates from a study of Marczynski et al.14 A questionnaire 
was applied at baseline in 1993. Blood samples were taken 
annually  (1993–1997)  during  medical  examinations. 
After clotting, serum samples were separated and fro-
zen immediately. In 2005, about 1,700 serum samples 
were available. A mortality follow-up was conducted 
until April 2007. One person with diagnosed LC in 1993 
was excluded from analysis. Samples from 33 partici-
pants obtained after diagnosis of MM or LC were also 
excluded. All participants provided informed consent. 
The study was designed according to rules guarding 
patient  privacy  and  an  updated  permission  from  the 
local ethics committee was obtained in 2005.
Measurement of sMrP, cA125, 
and cYFrA21-1
Of 626 participants, at least one serum sample was 
available for the evaluation of SMRP, CA125, and 
CYFRA21-1. Serum SMRP was analyzed using the 
commercial  ELISA  kit  MESOMARK  (provided 
by Fujirebio Diagnostics, Inc., Malvern, PA, USA)5 
according to Weber et al.13 CA125 was analyzed using 
the  ADVIA  Centaur  System  (Bayer  Health  Care, 
Wuppertal, Germany) and CYFRA21-1 was analyzed 
using the Elecsys 2010 System (Roche Diagnostics, 
Mannheim, Germany) according to the manufacturer’s 
instructions.
Measurement of creatinine and crP
Of 620 participants serum samples were available for 
the determination of creatinine and C-reactive protein 
(CRP) using the UniCel DxC 800 (Beckman Coulter, 
Krefeld, Germany) according to the manufacturer’s Assessment of confounding factors affecting tumor markers
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instructions. Serum creatinine is an indicator for renal 
diseases and CRP for hypertension and heart failure.
statistical Methods
Linear mixed models were applied to the data to estimate 
the effects of subject-related and sample-related fac-
tors on the marker levels. These models account for 
the correlated data structure because samples were 
collected repeatedly from the same subjects over time. 
Factors selected for analysis comprised age at entry in 
the surveillance cohort (with 1993 as reference year), 
gender, smoking status (current, former, and never 
smoker), duration of asbestos exposure (in decades), 
alterations of pleura, alterations of lung, creatinine, 
CRP, study center, storage time (9, 10, 11, 12 years 
after  collection),  and  later  diagnosed  MM  or  LC. 
Due to the skewed distribution of the marker con-
centrations  these  variables  were  log-transformed. 
Therefore, the effect estimates and their confidence 
intervals  were  re-transformed  via  the  exponential 
function presenting the factor of change in the marker 
concentrations.
Results
At baseline, the median age of the study population 
(n  =  626)  was  63  years  (range  53–70  years).  The 
majority  (91.9%)  of  the  participants  were  male 
(n = 575). Only few participants were current smokers 
(n = 90, 14.4%), whereas the majority were former 
(n = 348, 55.6%) or never smokers (n = 188, 30.0%). 
Median duration of asbestos exposure was 19 years 
(range 1–52 years). HRCT screens revealed that the 
majority (n = 410, 65.5%) of participants had pleu-
ral  (plaques  and  thickenings)  and/or  lung  (fibrotic) 
alterations.
Table 1 depicts the distribution of marker concen-
trations by median and inter-quartile range (IQR) and 
is further stratified by potential factors selected for 
analysis. Median SMRP concentration in the study 
group  was  0.72  nmol/l  (IQR  0.50–1.03  nmol/l). 
Median CA125 level was 10.40 KIU/l (IQR 7.40–14.95 
KIU/l), and median CYFRA21-1 value was 1.09 ng/ml 
(IQR 0.82–1.41 ng/ml).
The results of the linear mixed model for SMRP, 
CA125, and CYFRA21-1 are presented in Table 2. The 
factors gender, smoking status, CRP levels, alterations 
of pleura or lung, and development of MM had no 
significant influence on any of the analyzed markers. 
SMRP concentrations increased 1.02-fold (95% CI 
1.01–1.03, p = 0.0014) per age in years and 1.32-fold 
(95% CI 1.20–1.45, p  0.0001) per ng/ml serum cre-
atinine. In subjects 65 years median SMRP values 
(0.82 nmol/l) were significantly higher than in par-
ticipants 65 years (0.67 nmol/l, p = 0.0002). Also, 
median SMRP values in participants with 40 years 
of  asbestos  exposure  were  elevated  (0.98  nmol/l) 
compared to participants with 40 years of asbes-
tos exposure (0.70 nmol/l, p = 0.0002). Further, two 
centers  were  present  with  elevated  SMRP  levels. 
SMRP and CYFRA21-1 are not affected by storage 
time, as the median values show (Table 1). Also, indi-
vidual time courses did not show any trend (data not 
shown). However, storage time varied between nine 
and twelve years and showed a strong impact on the 
CA125 levels. Compared to the levels after nine years 
(median 8.90 KIU/l), the CA125 concentration was 
1.23-fold  (95%  CI  1.18–1.29,  p    0.0001)  higher 
after twelve years of storage. CYFRA21-1 correlated 
with LC (1.42-fold, 95% CI 1.12–1.79, p = 0.0033). 
Higher CYFRA21-1 values were observed for age 
(1.02-fold per year, 95% CI 1.01–1.02, p = 0.0005) 
and  rising  creatinine  values  (1.21-fold  per  ng/ml, 
95% CI 1.14–1.30, p  0.0001). CYFRA21-1 con-
centrations varied also in study centers.
Discussion
A major aim in cancer surveillance and screening pro-
grams is the diagnosis of the disease at early stages. 
The  use  of  tumor  markers  for  the  early  detection 
of cancer requires knowledge of factors that might 
influence the marker levels because the behavior of 
markers in healthy, unaffected subjects largely defines 
screening thresholds and hence specificity.4
We analyzed the influence of potential confound-
ers on serum concentrations of SMRP, CA125, and 
CYFRA21-1  in  a  healthy  surveillance  cohort. The 
assessment  of  specificity  and  sensitivity  to  detect 
MM and LC was not focus of this analysis. A detailed 
discussion about the correlation of SMRP, CA125, 
and CYFRA21-1 with MM and LC will be presented 
elsewhere.
The median SMRP concentration of 0.72 nmol/l 
found among 626 subjects is in accordance with SMRP 
levels  in  recent  studies  with  published  values  of Weber et al
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0.67  nmol/l  (n  =  86),  0.61  nmol/l  (n  =  112),  and 
0.77  nmol/l  (n  =  26).15–17  Also,  median  CA125 
(10.4 KIU/l) and CYFRA21-1 (1.09 ng/ml) are in line 
with levels reported in the literature, e.g. 9.2 KIU/l 
(n = 86) and 1.00 ng/ml (n = 27), respectively.15,18 
Median marker levels calculated in this study were 
based on an adequate number of subjects and might 
be  suitable  reference  values  for  use  in  screening 
programs.
Our analysis shows that the tumor markers are 
significantly influenced by various factors. A signifi-
cantly higher level of SMRP was observed in sub-
jects with an asbestos exposure of 40 years. While 
Pass  et  al  observed  no  correlation  between  expo-
sure duration and SMRP levels,19 Rodríguez Portal 
et  al  suggested  recently  that  increased  release  of 
SMRP in serum occurs as a consequence of asbestos 
exposure.20 Here we show that SMRP might indeed 
be  associated  with  asbestos  exposure  at  least  for 
long-term exposure. As this could be also reflect-
ing  an  age-related  effect,  we  analyzed  the  SMRP 
values in association with both age and duration of 
asbestos exposure. Higher SMRP values for partici-
pants with 40 years of asbestos exposure could be 
confirmed independently of age (data not shown). 
However, only 5% (n = 32) of the participants had 
an asbestos exposure of 40 years. Further analyses 
need to be done to validate the feasibility of SMRP 
as a marker of asbestos exposure.
Age was shown to be a statistically significant pre-
dictor of SMRP and CYFRA21-1 values. This is in 
contrast to our previous observation13 and the results 
of Pass et al.19 A possible explanation could be the age 
distribution in the study groups because this surveillance 
cohort comprised subjects of a median age of 63 years, 
whereas the previous groups were on average 20 years 
younger. Our results support a correlation between age 
and SMRP values, but only at older age. This should 
be taken into account in surveillance because MM is 
mainly diagnosed at 61–65 years.21
Creatinine  is  an  indicator  for  renal  diseases, 
which  are  potential  confounders  of  SMRP.5,22  A 
decreased  glomerular  filtration  rate  (GFR)  corre-
lated with increased SMRP values in a number of 
MM patients22 and with raised CYFRA21-1 levels 
in patients without evidence of neoplasia.23 Here we 
show that raised SMRP and CYFRA21-1 levels are 
indeed  correlated  with  increased  creatinine  levels 
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Table 2. Analysis of potential factors influencing SMRP, CA125, and CYFRA21-1 levels in serum. Values of exp(β) 1.00 
indicate a positive association between analyzed factor and marker, values 1.00 a negative association. Significant 
changes are marked in bold.
sMRp (nmol/l) cA25 (KIU/l) cYFRA2- (ng/ml)
exp(β) 95% cI p-value exp(β) 95% cI p-value exp(β) 95% cI p-value
Intercept 0.13 0.06–0.29 0.0001 6.39 2.73–14.96 0.0001 0.37 0.21–0.65 0.0005
Age (years) .02 .0–.0 0.00 1.00 0.99–1.02 0.5824 .02 .0–.02 0.0005
gender Male 1.03 0.86–1.22 0.7565 1.05 0.87–1.27 0.6341 0.94 0.83–1.06 0.3061
Female 1.00 – – 1.00 – – 1.00 – –
smoking never 1.00 – – 1.00 – – 1.00 – –
Former 0.97 0.88–1.08 0.6206 1.05 0.94–1.18 0.3834 0.95 0.88–1.03 0.1985
current 1.12 0.97–1.29 0.1338 0.94 0.80–1.10 0.4424 0.92 0.83–1.02 0.1185
creatinine 
(ng/ml)
.2 .20–.5 0.000 0.97 0.88–1.08 0.6159 .2 .–.0 0.000
crP (ng/ml) 0.99 0.94–1.06 0.8624 1.03 0.97–1.10 0.3000 1.02 0.97–1.06 0.4496
Asbestos 
exposure
10 years 1,00 – – 1.00 – – 1.00 – –
11–20 years 1.04 0.92–1.18 0.4850 .5 .0–.2 0.097 1.05 0.97–1.15 0.2408
21–30 years 0.92 0.80–1.05 0.2238 1.05 0.90–1.22 0.5188 1.03 0.93–1.13 0.5699
31–40 years 1.05 0.91–1.21 0.5144 1.08 0.92–1.26 0.3402 1.01 0.92–1.12 0.7990
40 years .29 .0–. 0.025 0.92 0.72–1.18 0.5013 1.01 0.86–1.19 0.8657
Pleural 
alterations1
0.98 0.89–1.08 0.6470 1.09 0.98–1.22 0.1161 1.07 0.99–1.14 0.0794
Lung 
alterations1
1.04 0.94–1.15 0.4566 1.00 0.89–1.12 0.9841 0.99 0.92–1.06 0.6933
study center 1 1.13 0.82–1.56 0.4518 1.17 0.82–1.67 0.3967 .27 .00–.2 0.00
2 . .00–.5 0.082 1.00 0.85–1.17 0.9695 0.96 0.86–1.07 0.4845
3 1.03 0.90–1.18 0.7008 0.92 0.80–1.07 0.2994 0.87 0.78–0.9 0.002
4 1.06 0.91–1.23 0.4456 0.99 0.84–1.17 0.9047 . .0–.25 0.0295
5 .20 .05–.8 0.0095 1.02 0.88–1.19 0.7841 1.01 0.91–1.11 0.8807
6 1.00 – – 1.00 – – 1.00 – –
storage time 9 years 1.00 – – 1.00 – – 1.00 – –
10 years 1.01 0.95–1.07 0.7684 .07 .0–.2 0.000 1.04 0.97–1.11 0.2669
11 years 1.00 0.95–1.07 0.8972 .7 .–.22 0.000 0.94 0.88–1.01 0.0983
12 years 1.01 0.95–1.08 0.6634 .2 .8–.29 0.000 0.95 0.89–1.02 0.1738
Lung cancer 1.24 0.90–1.71 0.1871 1.06 0.75–1.51 0.7268 .2 .2–.79 0.00
Malignant 
mesothelioma
1.06 0.83–1.34 0.6599 0.95 0.73–1.24 0.6959 0.94 0.79–1.12 0.4766
1Benign alterations of the pleura (plaques and thickenings) and lung (fibrotic) were detected by HRCT.Assessment of confounding factors affecting tumor markers
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supporting the observation that renal failure could 
lead  to  higher  marker  levels. Therefore,  measure-
ment of creatinine and estimation of GFR should be 
applied in surveillance to reduce the number of false-
positive cases.
In  some  study  centers  SMRP  and  CYFRA21-1 
showed altered values whereas CA125 was not affected. 
This might be caused by different sample handling 
procedures between blood drawing and freezing of 
serum. As results can be misleading if conditions of 
the  procedure  are  not  standardized,24  the  complete 
procedure, including clotting time and centrifugation, 
should be performed according to stringent protocols.
Recently, Roe et al raised the question if serum sam-
ples analyzed retrospectively are practical for the analy-
sis of the selected markers.25 Our results demonstrate 
that frozen serum samples are indeed suitable for the 
retrospective analysis of SMRP and CYFRA-21, but 
not for CA125. For CA125, higher levels were observed 
after a longer duration of storage (Table 2). This is in 
agreement with former observations that attribute the 
changes to storage rather than physiological effects.26 
Previously, we have indicated that SMRP is stable dur-
ing  long-term  storage13  and  this  study  confirms  our 
observation. To our knowledge, for CYFRA21-1 this is 
the first report of stability during long-term storage.
In the first prospective study analyzing SMRP a 
relatively high false-positive rate was observed by 
Park et al.6 The results indicated that SMRP appears 
not  to  be  suited  as  a  screening  marker  for  early 
detection of MM. It would be interesting if the higher 
number of false-positive cases may be due to factors 
identified in our study.
This analysis identified factors influencing SMRP, 
CA125, and CYFRA21-1 concentrations in serum. 
Age, serum creatinine, duration of asbestos exposure, 
sample handling procedures and storage time were 
significant confounders of serum marker levels. Taken 
these results into account might reduce the number of 
false-positive cases in screening programs and hence 
raise specificity.
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